Cytosorbents Co. (NASDAQ:CTSO) CFO Peter J. Mariani Acquires 11,363 Shares of Stock

Cytosorbents Co. (NASDAQ:CTSO) CFO Peter J. Mariani bought 11,363 shares of the business’s stock in a transaction on Wednesday, December 11th. The shares were acquired at an average price of $0.89 per share, for a total transaction of $10,113.07. Following the completion of the purchase, the chief financial officer now owns 361,363 shares in the company, valued at approximately $321,613.07. The trade was a 3.25 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

Cytosorbents Price Performance

NASDAQ CTSO opened at $1.01 on Friday. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. Cytosorbents Co. has a 1-year low of $0.70 and a 1-year high of $2.15. The stock has a market capitalization of $55.23 million, a price-to-earnings ratio of -2.81 and a beta of 0.57. The business’s fifty day moving average price is $0.98 and its 200-day moving average price is $1.02.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC increased its position in shares of Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares during the last quarter. Sargent Investment Group LLC grew its position in Cytosorbents by 13.4% during the third quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock valued at $2,439,000 after buying an additional 192,747 shares during the period. Atomi Financial Group Inc. purchased a new stake in Cytosorbents during the third quarter valued at approximately $51,000. Finally, CM Management LLC raised its position in Cytosorbents by 3.0% in the second quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock worth $598,000 after acquiring an additional 25,000 shares during the period. Institutional investors own 32.87% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on CTSO. StockNews.com started coverage on Cytosorbents in a report on Thursday. They set a “hold” rating on the stock. HC Wainwright restated a “neutral” rating and set a $1.00 target price on shares of Cytosorbents in a research note on Monday, November 11th.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.